Recently, Shenzhen Cell Valley successfully completed a landmark international delivery - the clinical-grade anti-CD7 retroviral vector independently developed by the company and industrially produced under GMP conditions was successfully delivered cross-border to the Children's University Hospital Tübingen, Germany, and officially used by Rupert, an academician of the German Academy of Sciences, a well-known European expert on pediatric hematology, and the former president of the Children's Hospital of the University of Tübingen, Germany. A clinical treatment project for relapsed and refractory T lymphoblastic lymphoma/leukemia led by Professor Handgretinger’s team. During the delivery process, we received great support and assistance from Shenzhen Customs, Shenzhen Airport and other relevant departments.

As one of the most influential centers for children's hematological diseases and cellular immunotherapy in Europe and even the world, the University Children's Hospital of Tübingen has long been an international leader in the fields of refractory and relapsed childhood leukemia, CAR-T/gene-modified immune cell therapy and other fields. Professor Handgretinger’s team has accumulated rich original clinical experience in cutting-edge areas such as CD7-targeted CAR-T/CAR-NK. Its related research has been published in top international medical journals for many times and has directly promoted the clinical transformation of multiple cell therapy technologies.

The anti-CD7 retroviral vector delivered this time was developed, amplified, quality controlled and released by Shenzhen Cell Valley relying on its mature clinical-grade retroviral vector GMP industrial production platform. It fully complies with the strict requirements of the EU and international mainstream regulatory systems for clinical gene vectors in terms of safety, titer, purity and consistency. This vector will be used to construct CD7-targeted gene-modified immune cells, which will directly serve the clinical treatment of patients with severe childhood hematological tumors.

This successful cross-border delivery and realization of "Made in China - Direct Clinical Application in Europe" not only reflects Shenzhen Cell Valley's comprehensive strength in high-end viral vector engineering, GMP quality system and international compliance delivery capabilities, but also marks that China's underlying key raw materials for cell and gene therapy have the ability to deeply participate in global high-level clinical research and treatment.

Shenzhen Cell Valley stated that it will continue to deepen its cooperation with top medical centers in Germany and Europe in the future, and promote more core cell and gene therapy technologies originating from China and serving the world in the fields of retroviruses, exosomes and eVLP next-generation gene delivery systems, and accelerate the benefits to patients around the world.

Professor Rupert and Professor Shi Yuanyuan take a group photo

University Children's Hospital of Tübingen, Germany

The Children's Hospital of the University of Tübingen in Germany, whose full name is the Children's and Adolescent Hospital of the University of Tübingen, is one of the top and oldest pediatric medical centers in Germany and is affiliated with the prestigious University Hospital of Tübingen. It combines the highest level of medical care, excellent research and comprehensive teaching and is the most important pediatric referral center in southwestern Germany. The hospital enjoys an international reputation in many cutting-edge fields, especially children's oncology and hematology (as a member of the National Comprehensive Cancer Center CCC), neonatal intensive care medicine (with a top-notch pnsive care unit NICU), inborn rs of, pediatric cardiology and cardiac surgery.